title: EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
abstract: Enteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical manifestations that may be caused by EV infections with varying degrees of severity. Among these viruses, EV-A71 and coxsackievirus (CV) CV-A16 from group A EVs attract the most attention because they are responsible for hand, foot and mouth disease (HFMD). Other EV-A viruses such as CV-A6 and CV-A10 were also reported to cause HFMD outbreaks in several countries or regions. Group B EVs such as CV-B3, CV-B5 and echovirus 30 were reported to be the main pathogens responsible for myocarditis and encephalitis epidemics and were also detected in HFMD patients. Vaccines are the best tools to control infectious diseases. In December 2015, China's Food and Drug Administration approved two inactivated EV-A71 vaccines for preventing severe HFMD.The CV-A16 vaccine and the EV-A71-CV-A16 bivalent vaccine showed substantial efficacy against HFMD in pre-clinical animal models. Previously, research on EV-B group vaccines was mainly focused on CV-B3 vaccine development. Because the HFMD pathogen spectrum has changed, and the threat from EV-B virus-associated severe diseases has gradually increased, it is necessary to develop multivalent HFMD vaccines. This study summarizes the clinical symptoms of diseases caused by EVs, such as HFMD, myocarditis and encephalitis, and the related EV vaccine development progress. In conclusion, developing multivalent EV vaccines should be strongly recommended to prevent HFMD, myocarditis, encephalitis and other severe diseases.
authors.affiliation: National Institutes for Food and Drug Control, Beijing 100050, China.
authors.forename: Qunying
authors.initials: Q
authors.lastname: Mao
authors.affiliation: National Institutes for Food and Drug Control, Beijing 100050, China.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Wang
authors.affiliation: National Institutes for Food and Drug Control, Beijing 100050, China.
authors.forename: Lianlian
authors.initials: L
authors.lastname: Bian
authors.affiliation: National Institutes for Food and Drug Control, Beijing 100050, China.
authors.forename: Miao
authors.initials: M
authors.lastname: Xu
authors.affiliation: National Institutes for Food and Drug Control, Beijing 100050, China.
authors.forename: Zhenglun
authors.initials: Z
authors.lastname: Liang
mesh_terms: D000818:Animals; D002681:China; D017277:Drug Approval; D055808:Drug Discovery; D018792:Encephalitis, Viral / Q000503:physiopathology / Q000517:prevention & control / Q000821:virology; D004770:Enterovirus / Q000145:classification / Q000276:immunology; D029821:Enterovirus A, Human / Q000276:immunology*; D029822:Enterovirus B, Human / Q000276:immunology; D004769:Enterovirus Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D005838:Genotype; D006232:Hand, Foot and Mouth Disease / Q000517:prevention & control*; D006801:Humans; D009205:Myocarditis / Q000503:physiopathology / Q000517:prevention & control / Q000821:virology; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
chemical_list: D015164:Vaccines, Inactivated; D014765:Viral Vaccines